Biopharma firms are grappling with a turbulent and complex policy landscape. The threat of 100% tariffs on imported branded drugs have fundamentally altered business strategy for firms, spurring dealmaking with the federal government in exchange for tariff relief. Heightened policy uncertainty is forcing manufacturers to reevaluate pricing and go-to-market strategies, with a severe expected revenue impact.
AlphaSense recently hosted a webinar with Dr. Robert Popovian, Chief Science Policy Officer at the Global Health Living Foundation to discuss these issues and more. This report leverages key insights from Dr. Popovian and those available in AlphaSense to explore the key policy shifts shaping the biopharma ecosystem.
